vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SANFILIPPO JOHN B & SON INC (JBSS). Click either name above to swap in a different company.
SANFILIPPO JOHN B & SON INC is the larger business by last-quarter revenue ($314.8M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
John B. Sanfilippo & Son Inc. (JBSS) is a leading US processor, marketer and distributor of high-quality tree nuts, peanuts, dried fruits, and value-added snack products. It serves retail, foodservice, and industrial ingredient customers primarily across North America, offering both branded and private label product lines.
ESPR vs JBSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $314.8M |
| Net Profit | — | $18.0M |
| Gross Margin | — | 18.8% |
| Operating Margin | 50.6% | 8.3% |
| Net Margin | — | 5.7% |
| Revenue YoY | 143.7% | 4.6% |
| Net Profit YoY | — | 32.1% |
| EPS (diluted) | $0.32 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $314.8M | ||
| Q3 25 | $87.3M | $298.7M | ||
| Q2 25 | $82.4M | $269.1M | ||
| Q1 25 | $65.0M | $260.9M | ||
| Q4 24 | $69.1M | $301.1M | ||
| Q3 24 | $51.6M | $276.2M | ||
| Q2 24 | $73.8M | $269.6M | ||
| Q1 24 | $137.7M | $271.9M |
| Q4 25 | — | $18.0M | ||
| Q3 25 | $-31.3M | $18.7M | ||
| Q2 25 | $-12.7M | $13.5M | ||
| Q1 25 | $-40.5M | $20.2M | ||
| Q4 24 | — | $13.6M | ||
| Q3 24 | $-29.5M | $11.7M | ||
| Q2 24 | $-61.9M | $10.0M | ||
| Q1 24 | $61.0M | $13.5M |
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 18.1% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 18.5% | ||
| Q1 24 | — | 18.1% |
| Q4 25 | 50.6% | 8.3% | ||
| Q3 25 | -11.4% | 9.0% | ||
| Q2 25 | 8.6% | 7.5% | ||
| Q1 25 | -34.0% | 10.8% | ||
| Q4 24 | -6.4% | 6.4% | ||
| Q3 24 | -31.0% | 6.2% | ||
| Q2 24 | 3.5% | 5.4% | ||
| Q1 24 | 52.5% | 6.7% |
| Q4 25 | — | 5.7% | ||
| Q3 25 | -35.9% | 6.3% | ||
| Q2 25 | -15.4% | 5.0% | ||
| Q1 25 | -62.2% | 7.7% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | -57.2% | 4.2% | ||
| Q2 24 | -83.9% | 3.7% | ||
| Q1 24 | 44.3% | 5.0% |
| Q4 25 | $0.32 | $1.53 | ||
| Q3 25 | $-0.16 | $1.59 | ||
| Q2 25 | $-0.06 | $1.15 | ||
| Q1 25 | $-0.21 | $1.72 | ||
| Q4 24 | $-0.14 | $1.16 | ||
| Q3 24 | $-0.15 | $1.00 | ||
| Q2 24 | $-0.33 | $0.85 | ||
| Q1 24 | $0.34 | $1.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $2.4M |
| Total DebtLower is stronger | — | $28.8M |
| Stockholders' EquityBook value | $-302.0M | $370.1M |
| Total Assets | $465.9M | $617.7M |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $2.4M | ||
| Q3 25 | $92.4M | $714.0K | ||
| Q2 25 | $86.1M | $585.0K | ||
| Q1 25 | $114.6M | $1.3M | ||
| Q4 24 | $144.8M | $336.0K | ||
| Q3 24 | $144.7M | $442.0K | ||
| Q2 24 | $189.3M | $484.0K | ||
| Q1 24 | $226.6M | $377.0K |
| Q4 25 | — | $28.8M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $14.6M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | — | $6.0M | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $6.4M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $-302.0M | $370.1M | ||
| Q3 25 | $-451.4M | $362.8M | ||
| Q2 25 | $-433.5M | $360.7M | ||
| Q1 25 | $-426.2M | $346.6M | ||
| Q4 24 | $-388.7M | $325.6M | ||
| Q3 24 | $-370.2M | $310.8M | ||
| Q2 24 | $-344.2M | $322.6M | ||
| Q1 24 | $-294.3M | $321.8M |
| Q4 25 | $465.9M | $617.7M | ||
| Q3 25 | $364.0M | $598.7M | ||
| Q2 25 | $347.1M | $597.6M | ||
| Q1 25 | $324.0M | $590.0M | ||
| Q4 24 | $343.8M | $545.3M | ||
| Q3 24 | $314.1M | $519.4M | ||
| Q2 24 | $352.3M | $515.6M | ||
| Q1 24 | $373.1M | $491.9M |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $62.5M |
| Free Cash FlowOCF − Capex | — | $40.0M |
| FCF MarginFCF / Revenue | — | 12.7% |
| Capex IntensityCapex / Revenue | 0.0% | 7.1% |
| Cash ConversionOCF / Net Profit | — | 3.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $32.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $62.5M | ||
| Q3 25 | $-4.3M | $32.1M | ||
| Q2 25 | $-31.4M | $36.5M | ||
| Q1 25 | $-22.6M | $-25.9M | ||
| Q4 24 | $-35.0M | $11.0M | ||
| Q3 24 | $-35.3M | $8.9M | ||
| Q2 24 | $-7.2M | $35.2M | ||
| Q1 24 | $53.8M | $5.3M |
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $7.3M | ||
| Q2 25 | — | $23.0M | ||
| Q1 25 | — | $-37.6M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-35.5M | $-3.0M | ||
| Q2 24 | $-7.3M | $24.4M | ||
| Q1 24 | $53.8M | $-1.3M |
| Q4 25 | — | 12.7% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | -14.4% | ||
| Q4 24 | — | -0.9% | ||
| Q3 24 | -68.7% | -1.1% | ||
| Q2 24 | -9.9% | 9.0% | ||
| Q1 24 | 39.0% | -0.5% |
| Q4 25 | 0.0% | 7.1% | ||
| Q3 25 | 0.0% | 8.3% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 4.5% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.3% | 4.3% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 2.4% |
| Q4 25 | — | 3.48× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | -1.29× | ||
| Q4 24 | — | 0.81× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 3.52× | ||
| Q1 24 | 0.88× | 0.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
